A Study of HRS7415 Tablets in Patients With Advanced Malignant Tumors
A Phase I Clinical Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS7415 Tablets in Patients With Advanced Malignant Tumors
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Denghui Gao
- Phone Number: +0518-81220121
- Email: denghui.gao@hengrui.com
Study Contact Backup
- Name: Huan Li
- Phone Number: +0518-81220121
- Email: huan.li@hengrui.com
Study Locations
-
-
Shandong
-
Jinan, Shandong, China, 250021
- Cancer Hospital Affiliated to Shandong First Medical University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subjects volunteered to participate in the clinical study, understood the study procedure and was able to sign informed consent in person.
- 18 to 75 years old, male or female.
- ECOG Performance Status of 0 or 1.
- The estimated survival time is ≥12 weeks.
- Subjects with advanced or metastatic malignancy confirmed by histopathology or cytology.
- Solid tumor subjects had measurable lesions that met RECIST 1.1 criteria.
- Adequate hematology and terminal organ function, with vital organ function meeting the upper and lower limits required by the protocol.
- Male subjects and fertile female subjects must agree to use medically approved contraception during the study period and for 6 months following the study; Fertile female subjects must have a negative serum human chorionic gonadotropin (HCG) test within 7 days prior to initial dosing and must be non-lactation blood pregnancy test must be negative and not lactation.
Exclusion Criteria:
- Subjects plan to receive any other antitumor therapy during the study period.
- Subjects received chemotherapy, radiotherapy, biotherapy, targeted therapy, or immunotherapy within 4 weeks prior to initial dosing.
- Major surgery other than diagnosis or biopsy was performed within 4 weeks prior to initial dosing.
- Received any other investigational drug or treatment that is not on the market within 4 weeks prior to initial dosing.
- The damage caused by any previous antineoplastic therapy has not recovered to grade ≤1.
- Imaging diagnosis showed tumor lesion or meningeal metastasis in the brain.
- Active heart disease in the 6 months prior to initial dosing.
- Had other malignancies within 5 years prior to first dosing.
- Subjects with poorly controlled hypertension and a previous history of hypertensive crisis or hypertensive encephalopathy.
- Having one of several factors affecting oral medication or having active gastrointestinal disease or other medical conditions that may result in significant influence on drug absorption, distribution, metabolism or excretion;
- Active hepatitis B and C;
- Serious infections that require intravenous antibiotics, antivirals or antifungals to control;
- History of immune deficiency or organ transplantation;
- Comorbidities or any other conditions that, in the investigator's judgment, seriously endanger patient safety or prevent patients from completing the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: HRS7415
|
Drug: HRS7415
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Dose-limiting toxicity (DLT)
Time Frame: From the beginning of first patient in (FPI) to the end of dose escalation phase up to approximately 10 months
|
From the beginning of first patient in (FPI) to the end of dose escalation phase up to approximately 10 months
|
|
maximum tolerated dose (MTD)
Time Frame: From the beginning of first patient in (FPI) to the end of dose escalation phase up to approximately 10 months
|
From the beginning of first patient in (FPI) to the end of dose escalation phase up to approximately 10 months
|
|
Phase II recommended dose (RP2D)
Time Frame: From the beginning of first patient in (FPI) to the end of dose escalation phase up to approximately 10 months
|
From the beginning of first patient in (FPI) to the end of dose escalation phase up to approximately 10 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Incidence, severity, duration, and association of adverse events (AE) and severe adverse events (SAE) with the study drug, in addition to abnormalities in vital signs, electrocardiogram, and laboratory tests
Time Frame: From the beginning of first patient in (FPI) to the end of study up to approximately 2 years
|
From the beginning of first patient in (FPI) to the end of study up to approximately 2 years
|
|
Single dose parameters: Peak plasma concentration (Cmax) of HRS7415 and its main metabolite after single dosing
Time Frame: From the beginning of first patient in (FPI) to the end of study up to approximately 2 years
|
From the beginning of first patient in (FPI) to the end of study up to approximately 2 years
|
|
Single dose parameters: Time to peak (Tmax) of HRS7415 and its main metabolite after single dosing
Time Frame: From the beginning of first patient in (FPI) to the end of study up to approximately 2 year
|
From the beginning of first patient in (FPI) to the end of study up to approximately 2 year
|
|
Single dose parameters: Area under the curve from 0 to the last measurable concentration time point t (AUC0-t) of HRS7415 and its main metabolite after single dosing (if applicable)
Time Frame: From the beginning of first patient in (FPI) to the end of study up to approximately 2 years
|
From the beginning of first patient in (FPI) to the end of study up to approximately 2 years
|
|
Single dose parameters: Area under the time curve from 0 to infinity (AUC0-inf) of HRS7415 and its main metabolite after single dosing (if applicable)
Time Frame: From the beginning of first patient in (FPI) to the end of study up to approximately 2 years
|
From the beginning of first patient in (FPI) to the end of study up to approximately 2 years
|
|
Single dose parameters: Half-value period (t1/2) of HRS7415 and its main metabolite after single dosing (if applicable)
Time Frame: From the beginning of first patient in (FPI) to the end of study up to approximately 2 years
|
From the beginning of first patient in (FPI) to the end of study up to approximately 2 years
|
|
Single dose parameters: Apparent volume of distribution (Vz/F) of HRS7415 and its main metabolite after single dosing (if applicable)
Time Frame: From the beginning of first patient in (FPI) to the end of study up to approximately 2 years
|
From the beginning of first patient in (FPI) to the end of study up to approximately 2 years
|
|
Single dose parameters: Apparent clearance (CL/F) of HRS7415 and its main metabolite after single dosing (if applicable)
Time Frame: From the beginning of first patient in (FPI) to the end of study up to approximately 2 years
|
From the beginning of first patient in (FPI) to the end of study up to approximately 2 years
|
|
Multiple dose parameters: Steady state peak concentration (Cmax,ss) of HRS7415 and its main metabolite after multiple dosing
Time Frame: From the beginning of first patient in (FPI) to the end of study up to approximately 2 years
|
From the beginning of first patient in (FPI) to the end of study up to approximately 2 years
|
|
Multiple dose parameters: Time to peak (Tmax, ss) of HRS7415 and its main metabolite after multiple dosing
Time Frame: From the beginning of first patient in (FPI) to the end of study up to approximately 2 years
|
From the beginning of first patient in (FPI) to the end of study up to approximately 2 years
|
|
Multiple dose parameters: Steady valley concentration (Cmin,ss) of HRS7415 and its main metabolite after multiple dosing
Time Frame: From the beginning of first patient in (FPI) to the end of study up to approximately 2 years
|
From the beginning of first patient in (FPI) to the end of study up to approximately 2 years
|
|
Multiple dose parameters: Area under steady-state drug concentration-time curve (AUCss) of HRS7415 and its main metabolite after multiple dosing
Time Frame: From the beginning of first patient in (FPI) to the end of study up to approximately 2 years
|
From the beginning of first patient in (FPI) to the end of study up to approximately 2 years
|
|
Multiple dose parameters: Drug storage ratio (Rac) of HRS7415 and its main metabolite after multiple dosing
Time Frame: From the beginning of first patient in (FPI) to the end of study up to approximately 2 years
|
From the beginning of first patient in (FPI) to the end of study up to approximately 2 years
|
|
Efficacy endpoints: Objective response rate (ORR)
Time Frame: From the beginning of first patient in (FPI) to the end of study up to approximately 2 years
|
From the beginning of first patient in (FPI) to the end of study up to approximately 2 years
|
|
Efficacy endpoints: Disease control rate (DCR)
Time Frame: From the beginning of first patient in (FPI) to the end of study up to approximately 2 years
|
From the beginning of first patient in (FPI) to the end of study up to approximately 2 years
|
|
Efficacy endpoints: Duration of response (DoR)
Time Frame: From the beginning of first patient in (FPI) to the end of study up to approximately 2 years
|
From the beginning of first patient in (FPI) to the end of study up to approximately 2 years
|
|
Efficacy endpoints: Progression-free survival (PFS)
Time Frame: From the beginning of first patient in (FPI) to the end of study up to approximately 2 years
|
From the beginning of first patient in (FPI) to the end of study up to approximately 2 years
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- HRS7415-I-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.